170 related articles for article (PubMed ID: 37373969)
1. Comparison of Interleukin-6 with Other Markers in Diagnosis of Ovarian Cancer.
Bizoń M; Awiżeń-Panufnik Z; Sawicki W
J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373969
[TBL] [Abstract][Full Text] [Related]
2. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors.
Chen F; Shen J; Wang J; Cai P; Huang Y
Cancer Manag Res; 2018; 10():1313-1318. PubMed ID: 29861641
[TBL] [Abstract][Full Text] [Related]
3. Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer.
Li H; Sun L; Chen L; Kang Z; Hao G; Bai F
J Med Biochem; 2022 Feb; 41(1):71-78. PubMed ID: 35431651
[TBL] [Abstract][Full Text] [Related]
4. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
5. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
8. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer.
Wan Q; Liu Y; Lv B; Chen X
Iran J Public Health; 2021 Jun; 50(6):1197-1205. PubMed ID: 34540740
[TBL] [Abstract][Full Text] [Related]
10. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
[TBL] [Abstract][Full Text] [Related]
11. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
12. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
14. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
16. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis.
Kocabaş E; Sarikçioğlu A; Aksaray N; Seydaoğlu G; Seyhun Y; Yaman A
Turk J Pediatr; 2007; 49(1):7-20. PubMed ID: 17479639
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
18. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
19. Comparison of specific ovarian tumor markers by elecsys analyzer 2010.
Hasanbegovic L; Alicelebic S; Sljivo N
Acta Inform Med; 2015 Apr; 23(2):86-9. PubMed ID: 26005273
[TBL] [Abstract][Full Text] [Related]
20. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]